The £5.8m trial, investigating the effects of the simvastatin drug, will involve people in Leeds after research leaders announced YBRC’s own Dr Helen Ford will help co-ordinate the programme.
Simvastatin, a cheap cholesterol lowering drug, will be tested on people with the secondary progressive form of MS.
Dr Ford, clinical lead for the West Yorkshire MS Treatment Programme, told the Yorkshire Post: “It’s great news that this large trial has been funded in secondary progressive MS. There are currently no effective treatments available to slow down the worsening of disability in progressive MS. As a collaborator in this project I’m pleased that people with MS in Leeds will have the opportunity to take part.”
The announcement comes after the phase two trial into the drug was published in 2014, involving 140 people suffering from the condition. It found that those taking high doses of simvastatin had a significant reduction in the rate of brain atrophy over the two years of the study.
The third phase will involve more than 1,000 people who have MS. Recruitment for the trial will take place later in 2017. Professor Sue Pavitt, from the University of Leeds, has also been confirmed as a collaborator for the new study. The cost, almost £6m, will be funded by National Institute for Health Research, the MS Society UK, the National MS Society, the NHS and UK universities.
Read more at: http://www.yorkshirepost.co.uk/news/leeds-patients-to-be-involved-in-ground-breaking-6m-ms-treatment-trial-1-8544268